Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of everolimus + letrozole in recurrent endometrial cancer
2008-006841-25Phase 2Terminated
- Sponsor
- Istituto Oncologico della Svizzera Italiana
- Start
- May 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and letrozole in endometrial cancer (EC) and Endometrial Neoplasia, sponsored by Istituto Oncologico della Svizzera Italiana. Primary endpoint: Objective clinical response. Started May 2009; status: terminated.
02
Drugs
everolimusletrozole
03
Conditions
endometrial cancer (EC)Endometrial Neoplasia
Beyond the preview
Go deeper on 2008-006841-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006841-25.